MapLight Therapeutics, Inc. MPLT

MPLT Company Overview

MapLight Therapeutics, Inc. is a privately held clinical-stage biotechnology company focused on developing precision medicines for central nervous system (CNS) and neuropsychiatric disorders. The company operates within the biotechnology and pharmaceutical industries, with an emphasis on neuroscience-driven drug discovery and genetically informed therapeutics. Its core strategy centers on identifying biological mechanisms associated with severe psychiatric and neurological diseases and translating those findings into targeted therapeutics. Publicly available information indicates that the company’s lead development efforts have focused on schizophrenia and related neuropsychiatric conditions.

The company was founded in 2019 by researchers and biotechnology executives with expertise in neuroscience, genetics, and drug development. MapLight emerged from advances in human genetics and translational neuroscience, seeking to apply precision medicine approaches more commonly associated with oncology to psychiatric disorders. The company has positioned itself around the use of genetically validated targets, biomarker-informed clinical development, and neuroscience-focused therapeutic platforms intended to improve efficacy and patient selection in complex CNS diseases.